Last reviewed · How we verify
Cravit-based sequential therapy
Cravit-based sequential therapy uses levofloxacin (a fluoroquinolone antibiotic) as part of a multi-drug sequential regimen to eradicate Helicobacter pylori infection.
Cravit-based sequential therapy uses levofloxacin (a fluoroquinolone antibiotic) as part of a multi-drug sequential regimen to eradicate Helicobacter pylori infection. Used for Helicobacter pylori infection eradication (sequential therapy regimen).
At a glance
| Generic name | Cravit-based sequential therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Fluoroquinolone antibiotic (as part of sequential therapy regimen) |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
This is a sequential therapy approach for H. pylori eradication that incorporates Cravit (levofloxacin), a broad-spectrum fluoroquinolone antibiotic. Sequential therapy typically involves administering different antibiotic combinations in sequence over a treatment period to improve eradication rates and reduce antibiotic resistance. Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication in H. pylori.
Approved indications
- Helicobacter pylori infection eradication (sequential therapy regimen)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort)
- Tendinopathy
- QT prolongation
- Photosensitivity
Key clinical trials
- Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients (PHASE4)
- Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy (PHASE4)
- The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cravit-based sequential therapy CI brief — competitive landscape report
- Cravit-based sequential therapy updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI